Immusoft's Series B Round

Immusoft raised a round of funding on January 05, 2018.

Immusoft is a biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells. The first ISP-based treatment Immusoft will advance to h…

Articles about Immusoft's Series B Round: